Formulary
Teduglutide: Indications, Dosing, Side Effects and Interactions
Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine.
MedNext Academy | 3 min read
Teduglutide: Indications, Dosing, Side Effects and Interactions
Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine.
Drug action
Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine.
Indications and dose
**Short bowel syndrome (initiated under specialist supervision)**
- **Adult** (By Subcutaneous Injection): 0.05 mg/kg once daily, dose to be administered to alternating quadrants of the abdomen; alternatively the thigh can be used, for optimal injection volume per body weight, consult product literature. Review treatment after 6 months.
**Short bowel syndrome (initiated under specialist supervision) for teduglutide**
- **Child 1-17 years** (By subcutaneous injection): 0.05 mg/kg once daily, dose to be administered to alternating quadrants of the abdomen; alternatively the thigh can be used, for optimal injection volume per body weight and when to review treatment, consult product literature.
Cautions
Abrupt withdrawal of parenteral support (reduce gradually with concomitant monitoring of fluid status); cardiac insufficiency; cardiovascular disease; colo-rectal polyps; hypertension
Contraindications
Active or suspected malignancy; history of gastro-intestinal malignancy (in previous 5 years)
Side effects
Common or very common Anxiety; appetite decreased; congestive heart failure; cough; dyspnoea; fluid imbalance; gallbladder disorders; gastrointestinal discomfort; gastrointestinal disorders; gastrointestinal stoma complication; headache; influenza like illness; insomnia; nausea; pancreatitis; peripheral oedema; respiratory tract infection; vomiting Uncommon Syncope
Interactions
**Other interactions (2):**
- An in vitro study indicates that teduglutide does not inhibit cytochrome P450 drug metabolising enzymes.
- Based upon the pharmacodynamic effect of teduglutide, there is a potential for increased absorption of concomitant medicinal products (see section 4.4).
Pregnancy
Specialist sources indicate use if necessary-no human data available. D
Breast feeding
Manufacturer advises avoid-toxicity in animal studies.
Renal impairment
Dose adjustments Use half the daily dose if creatinine clearance is less than 50 mL/minute, M see Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Teduglutide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

